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The ability of an organism to sense and store nutrients is vital to survival. The liver is the major organ responsible for con-
verting excess dietary carbohydrate to lipid for storage. An elegant molecular pathway has evolved that allows increased
glucose flux into hepatocytes to generate a signaling molecule, xylulose 5-phosphate, that triggers rapid changes in glyco-
lytic enzyme activities and nuclear import of a transcription factor, ChREBP,which coordinates the transcriptional regulation
of enzymes that channel the glycolytic end-products into lipogenesis. Further understanding of this metabolic cascade
should provide insights on conditions such as fatty liver, obesity, and the metabolic syndrome.Introduction
In mammals, the liver is the principle organ responsible for main-
taining long-term energy needs by the conversion of carbohy-
drate to fat for storage. Upon consumption of excess carbo-
hydrate, digestion yields simple sugars that are converted to
pyruvate (glycolysis), which is either oxidized to provide energy
or channeled into pathways for synthesis of fatty acids (lipo-
genesis) when energy is available. The coordinated regulation
of these processes allows for efficient utilization of dietary car-
bohydrate. Key enzymes of these pathways are acutely regu-
lated by posttranslational, allosteric mechanisms triggered by
changes in hormones and nutrients. Additionally, long-term ex-
posure of hepatocytes to elevated glucose and insulin results in
increased quantities of these key enzymes through enhanced
transcription and translation.
Ingestion of carbohydrate results in elevated blood glucose,
which rapidly triggers insulin release from b cells of the endo-
crine pancreas. It has long been recognized that insulin in-
duces the transcription of lipogenic enzymes in liver. This effect
of insulin is mediated by the sterol regulatory element binding
protein-1c (SREBP-1c), a transcription factor of the basic helix-
loop-helix leucine zipper family (Horton et al., 2002). In isolated
rodent hepatocytes, insulin exposure increases the amount of
mRNA for SREBP-1c and its lipogenic target genes (Foretz
et al., 1999). Conversely, streptozotocin treatment of mice to
abolish insulin secretion is accompanied by a fall in hepatic
SREBP-1c expression (Shimomura et al., 1999). Mice engineered
to selectively express active SREBP-1c in liver show enhanced
fatty acid synthesis rates and triglyceride accumulation (4-fold)
(Horton et al., 1998), whereas mice devoid of SREBP-1c exhibit
diminished hepatic expression of lipogenic enzymes and a 50%
reduction in the rate of fatty acid production (Liang et al., 2002).
Discovery and characterization of ChREBP
More recently, the recognition that glucose, independent of insu-
lin, also serves as an effector of lipogenic gene expression has
gained attention. When primary hepatocytes are cultured in
high glucose and minimal insulin, the mRNA levels of acetylCELL METABOLISM 4, 107–110, AUGUST 2006 ª2006 ELSEVIER INC.CoA carboxylase (ACC), fatty acid synthase (FAS), and liver-
type pyruvate kinase (L-PK) are increased (Towle et al., 1997;
Vaulont et al., 2000). These genes continue to be up-regulated
by high-carbohydrate feeding even in mice lacking SREBP-1c
(Liang et al., 2002), suggesting regulation by another transcrip-
tion factor(s). The carbohydrate-responsive promoter elements
of these geneswere identified and conform to the sequence rec-
ognized by members of the basic helix-loop-helix family of tran-
scription factors (Bergot et al., 1992; Shih et al., 1995). Using the
DNA motif of the L-PK gene as an affinity tag, the Uyeda group
purified a transcription factor from nuclear extracts of liver tissue
from carbohydrate-fed rats and named this protein the carbohy-
drate response element binding protein, ChREBP (Yamashita
et al., 2001). The nuclear abundance of DNA binding-competent
ChREBPwashigh in livers of carbohydrate-fed rats, low in liver of
high-fat fed rats, andnearly undetectable in rats following starva-
tion. ChREBP had been previously identified as one of 17 genes
deleted in Williams-Beuren syndrome (WBSCR14) (Cairo et al.,
2001), also called MondoB, and while this genetic disorder en-
tails developmental abnormalities of the heart, nervous system,
and skin, it has nowbeen recognized that about 75%ofWBSpa-
tients exhibit impaired glucose tolerance or silent diabetes that
may be related to a loss of ChREBP (Pober et al., 2001).
Structure, function, and regulation of ChREBP
The tissue distribution of ChREBP has been established largely
by the presence of its mRNA using Northern analysis or in situ
hybridization methods. ChREBP mRNA is first detected in the
mouse liver at embryonic stage E12.5 (Cairo et al., 2001), and
in the adult, the rank order of expression in various tissues is
liver >> adipose > intestine > kidney = muscle (Iizuka et al.,
2004; Yamashita et al., 2001). ChREBP mRNA has also been
detected in distinct brain regions (Cairo et al., 2001) and in
rat pancreatic islets (Wang and Wollheim, 2002).
ChREBP is a large transcription factor of nearly 100 kDa,
consisting of approximately 850 amino acids (Figure 1A). This
protein is highly conserved among species, exhibiting 82%
amino acid sequence identity among human, rat, and mouseDOI 10.1016/j.cmet.2006.06.008 107
M I N I R E V I E WFigure 1. Schematic depiction and characterization
of ChREBP
A) Schematic depiction of ChREBP indicating vari-
ous functional domains: nuclear export signal
(NES); nuclear localization signal (NLS); basic helix-
loop-helix/Zipper DNA binding domain (bHLH/ZIP)
and proline-rich domains implicated in protein-
protein interactions. Also shown are the amino acid
residues phosphorylated by PKA (Ser196, Ser626,
and Thr666) and AMPK (Ser568) that regulate the cel-
lular localization and DNA binding capacity of the
murine ChREBP (Kawaguchi et al., 2001, 2002). A
glucose-sensing domain has been identified consist-
ing of an N-terminal LID (inhibitory at low glucose)
and C-terminal glucose-responsive element (Li et al.,
2006).
B)Characterization of ChREBPs. Distribution of RNA
was determined by Northern analysis (de Luis et al.,
2000; Iizuka et al., 2004; Yamashita et al., 2001)
and in situ hybridization (Cairo et al., 2001) revealing
major sites of expression.(Cairo et al., 2001). Orthologs are also evident in Drosophila and
C. elegans, suggesting an evolutionarily conserved role for this
transcription factor (Li et al., 2006). ChREBP contains several
functional domains including nuclear export and import signals,
a DNA binding motif of the bHLH/ZIP type, and proline-rich
regions implicated in protein-protein interactions.
ChREBP interacts with Max-like protein X (Mlx) (Cairo et al.,
2001; Stoeckman et al., 2004) to form a heterotetramer that
binds to the L-PK gene promoter (Figure 2). This L-PK enhancer
element consists of two E-boxes (C[C/A]CG[G/T]G) separated
by five nucleotides, and ChREBP/Mlx binding depends on
both the sequence and spacing of these motifs (Shih et al.,
1995; Yamashita et al., 2001). Mlx is an essential component
of the ChREBP/Mlx complex by its ability to enhance DNA bind-
ing but is relatively abundant, stable, and unlikely to confer reg-
ulatory properties due to nutrient or hormone signaling (Cairo
et al., 2001; Stoeckman et al., 2004). ChREBP is a rather labile108protein, with an estimated half-life of 30 min (Cairo et al., 2001),
that undergoes nutrient-regulated allosteric modifications qual-
ifying this protein as the metabolic sensor of the ChREBP/Mlx
dimer.
The regulation of ChREBP protein is relatively simple and ef-
ficient, and involves phosphorylation-dependent mechanisms
responsive to feeding (glucose and fatty acids) and fasting (glu-
cagon) (Figure 3). In addition, a glucose-sensitive protein do-
main has been identified in cell-based systems (Li et al., 2006).
When serum glucose is elevated, the isoforms of glucose trans-
porter (GLUT2, aka SLC2A2) and kinase (hexokinase IV) present
in the hepatocyte allow for rapid uptake and equilibration of in-
tracellular glucose levels. This flux of glucose promotes the for-
mation of xylulose-5-phosphate (Xu-5-P), by the hexose mono-
phosphate shunt pathway, which activates protein phosphatase
2A (PP2A) to dephosphorylate ChREBP and promote its nuclear
localization and DNA binding. This series of events has beenFigure 2. Acute regulation of ChREBP activity by
hormone/nutrient-mediated changes in protein
phosphorylation
Phosphorylated ChREBP is actively excluded from
the nucleus and sequestered in the cytosol by its as-
sociation with 14-3-3, thereby rendering ChREBP an
inactive transcription factor. Hepatocyte exposure to
glucose results in an elevated xylulose 5-phosphate
(Xu-5-P) level, which promotes the action of protein
phosphatase 2A (PP2A) and allows for nuclear trans-
location of ChREBP (these processes shown by
green arrows). Nuclear ChREBP dimerizes with Mlx
and binds carbohydrate responsive elements in the
promoters of target genes such as liver pyruvate ki-
nase (L-PK) to increase transcription. Conversely,
glucagon and fatty acids increase the activities of
cAMP- (PKA) and AMP-dependent kinases (AMPK)
that phosphorylate ChREBP to reduce DNA binding
capacity and promote nuclear exclusion of ChREBP
(shown by red arrows).CELL METABOLISM : AUGUST 2006
M I N I R E V I E WFigure 3. The central role of ChREBP in linking gly-
colysis and lipogenesis in hepatocytes
Catabolism of glucose yields pyruvate, which can be
channeled into fatty acid synthesis. Proteins are indi-
cated in italicized uppercase letters, metabolic inter-
mediates in lowercase letters. The allosteric regula-
tion of early steps in glycolysis are indicated in
blue: xylulose-5-phosphate (Xu-5-P) and fructose-
2,6-bisphosphate (Fru-2,6-P2) positively affect key
enzymes PP2A, the kinase moiety of the bifunctional
enzyme PF2K-Pase, and phosphofructokinase
(PFK). Transcriptional regulation of the terminal
step of glycolysis (via L-PK) and key enzymes of lipo-
genesis is controlled by ChREBP (shown in red).
Concomitant production of NADPH by the hexose
monophosphate shunt pathway (HMP Shunt) in the
production of Xu-5-P and the recycling of pyruvate
from citrate-liberated oxaloacetate (OAA) by malic
enzyme (ME) provides reducing equivalents neces-
sary for fatty acid synthesis.observed in primary hepatocytes exposed to high glucose, with
Xu-5-P levels increased within 30 min, nuclear accumulation of
GFP-tagged ChREBP evident within 3 hr, and increased L-PK
transcription apparent shortly after 3 hr (Kabashima et al.,
2003). Upon starvation or high-fat feeding, intrahepatic levels
of cAMP and AMP are elevated to activate protein kinase A
(PKA) and AMP-dependent protein kinase (AMPK), respectively
(Figure 2). PKA-mediated phosphorylation of Thr666, located in
the DNA binding domain, and AMPK-mediated modification of
Ser568 inhibits the DNA binding capacity of ChREBP (Kawagu-
chi et al., 2001, 2002). PKA-dependent phosphorylation of
Ser196, which is adjacent to the nuclear localization signal
and falls immediately between the inhibitor (LID) and glucose-
activated (GRACE) portions of the recently described glucose-
sensing module (Li et al., 2006), promotes interaction with
14-3-3 and thus sequesters ChREBP in the cytosol (Kawaguchi
et al., 2001; Merla et al., 2004). Therefore, the phosphorylated
form of ChREBP is rendered inactive by virtue of its subcellular
compartmentalization and diminished DNA binding capacity.
The regulation of ChREBP transcription and translation is less
well understood. It has been observed that ChREBP mRNA lev-
els are elevated in insulinoma cells upon exposure to high glu-
cose levels, and nuclear run-on assays suggest that this occurs
as a result of increased transcription (Wang and Wollheim,
2002). ChREBP mRNA levels are increased during the differen-
tiation of the mouse adipocyte cell line 3T3-L1, a process that is
further enhanced by the presence of troglitazone, a PPARg li-
gand (He et al., 2004). Polyunsaturated fatty acids have been
observed to suppress ChREBP activity in primary hepatocytes
by increasing the decay rate of ChREBP mRNA (Dentin et al.,
2005). The precise molecular mechanisms by which these tran-CELL METABOLISM : AUGUST 2006scriptional and translational regulatory processes occur to con-
trol ChREBP activity await further investigation.
Biological role of ChREBP revealed by deletion
and overexpression studies
The tissue distribution, regulation, and DNA binding properties
of ChREBP/Mlx strongly suggested that ChREBP was the elu-
sive glucose-sensing, lipogenic transcription factor. A variety
of in vivo studies have now confirmed that contention.
Primary hepatocytes transfected with ChREBP and L-PK-re-
porter plasmids exhibit increased reporter activity when ex-
posed to high glucose (Kawaguchi et al., 2002; Yamashita
et al., 2001) This response can be exaggerated if one transfects
with a ChREBP variant that has alanines substituted for the
PKA- and AMPK-dependent phosphorylation sites (Kawaguchi
et al., 2002). The essential role of ChREBP in this transcriptional
response has been defined by the failure of glucose to induce
target gene expression when cells are transfected with silencing
RNA specific to ChREBP (Dentin et al., 2004), or when hepato-
cytes are obtained from Chrebp null mice (Ishii et al., 2004).
An alternate approach using a dominant negative form of Mlx
has confirmed that the ChREBP/Mlx complex controls the glu-
cose-responsive upregulation of L-PK, ACC, FAS, and other
lipogenic target genes (Ma et al., 2005).
The ultimate confirmation of a role for ChREBP in glucose and
lipid homeostasis camewith the characterization ofmice lacking
this gene (ChREBP2/2) (Iizuka et al., 2004). ChREBP2/2 mice
are viable, born in the expected Mendelian distribution, and ap-
pear to have a normal life span. When maintained on a standard
rodent diet, the knockout mice display larger, glycogen-laden
livers, smaller adipose depots, and decreased plasma free fatty109
M I N I R E V I E Wacid levels as compared to their wild-type littermates. The he-
patic mRNA expression level of nearly every enzyme needed
for lipogenesis is decreased in the knockout mice, and this re-
sults in a 65% reduction in fatty acid synthesis rates. This occurs
despite normal levels of SREBP-1c mRNA and the nuclear form
of the SREBP-1 protein in livers of the ChREBP2/2mice. These
findings suggest that in the absence of ChREBP the liver fails to
efficiently take up and utilize circulating glucose for the produc-
tion of fatty acids.
The ChREBP2/2 mice also show signs of insulin resistance,
exhibiting decreased glucose clearance following intraperito-
neal injection of a glucose bolus, and delayed glucose clearance
following an insulin dose. The measurement of glycolytic inter-
mediates in the liver supports the hypothesis that diminished ex-
pression of L-PK results in a build-up of substrate, phosphoenol
pyruvate, and upstream metabolites including glucose-6-
phosphate (Figure 3). This results in diminished glycolytic flux
and enhanced hepatic glycogen accumulation, which can be
exacerbated if the knockout mice are presented with a high-
starch diet. Interestingly, ChREBP2/2 mice appear to be ex-
tremely intolerant of diets containing substantial fructose or
sucrose, rapidly losing weight, exhibiting hypothermia and be-
coming moribund within days. This appears to be, in part, due
to diminished expression of enzymes required for fructose entry
into glycolysis. Overall, the loss of hepatic ChREBP results in
impaired glucose flux through the glycolytic pathway for the
production of pyruvate and lipids.
Future directions
The discovery and characterization of this fascinating transcrip-
tion factor has answered many questions, but raised many
more. For example, what are the roles of this protein in tissues
other than liver, particularly cells and tissues that are glucose-
sensitive (b cells of the pancreas, or hypothalamic neurons).
Does dysregulation of ChREBP contribute to disorders associ-
atedwith lipid accumulation such as fatty liver, insulin resistance
and diabetes, and the metabolic syndrome?
The ability of an organism to sense and store nutrients is vital
to survival. During fasting, glucagon secretion and mobilization
of adipose-derived fatty acids result in increased hepatic levels
of cAMP and AMP, thus suppressing the actions of lipogenic
transcription factors ChREBP and SREBP-1c. Conversely, dur-
ing feeding, hyperglycemia and insulin release cause, respec-
tively, activation of ChREBP and SREBP-1c, allowing for energy
storage through lipogenesis. These would be highly adaptive re-
sponses in animals subjected to feast and famine. However, in
most industrialized societies, famine is a rare event. Therefore
understanding ChREBP and its role in glucose and lipid metab-
olism may shed light on ‘‘feast-based’’ mechanisms that lead to
obesity, diabetes, and the metabolic syndrome.
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